Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults
The DOI matches its Crossref record.
Abstract
BACKGROUND: Anticonvulsant drugs have multiple mechanisms of action. Recent in vivo MRS studies suggest that cerebral gamma-aminobutyric acid (GABA) increases occur with the administration of certain anticonvulsants in humans. OBJECTIVE: To investigate the effect of topiramate, gabapentin, and lamotrigine on cerebral GABA concentrations in healthy volunteers and correlate the GABA concentrations with serum drug levels. METHODS: Seventeen healthy adults were randomly assigned to receive topiramate, gabapentin, and lamotrigine and underwent GABA measurements using a 4.1-T magnet from a 13.5-mL volume over the occipital region. GABA concentrations and serum levels were measured at 3 and 6 hours following administration of an acute single dose of one of the drugs. Thereafter, drugs were titrated over 4 weeks to target doses, with GABA measurements performed at 2 and 4 weeks. RESULTS: Cerebral GABA concentrations rose 70% in the acute phase compared with baseline for topiramate. GABA rose 48% at 6 hours with gabapentin but not with lamotrigine. With long-term dosing and once target doses were achieved at 4 weeks, significant elevations in GABA were observed compared with baseline for all three drugs (topiramate 46%, gabapentin 25%, lamotrigine 25%). CONCLUSION: This study demonstrates that single doses of topiramate and gabapentin increase cerebral GABA concentrations acutely (hours) in healthy individuals, but all drugs at clinically utilized doses increase cerebral GABA at 4 weeks. These results suggest that the mechanisms of action of anticonvulsant drugs are more complex and are likely to be multiple in nature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Suppression of cortical spreading depression in migraine prophylaxis
Ayata, C., Jin, H., Kudo, C., Dalkara, T., & Moskowitz, M. A. (2006) · Annals of Neurology · doi:10.1002/ana.20778 · Cited by 570
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489
Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy
Mula, M., & Sander, J. W. (2007) · Drug Safety · doi:10.2165/00002018-200730070-00001 · Cited by 306
13 C MRS studies of neuroenergetics and neurotransmitter cycling in humans
Rothman, D. L., De Feyter, H. M., de Graaf, R. A., Mason, G. F., & Behar, K. L. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1772 · Cited by 290
Brower, K. J., Myra Kim, H., Strobbe, S., Karam‐Hage, M. A., Consens, F., & Zucker, R. A. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00706.x · Cited by 179
“Its putative actions of enhancing GABA and modulating glutamate systems in the brain are consistent with its sleep-promoting effects (Dooley et al., 2007; Kuzniecky et al., 2002).”
BackgroundCai, K., Nanga, R. P., Lamprou, L., Schinstine, C., Elliott, M., Hariharan, H., Reddy, R., & Epperson, C. N. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.142 · Cited by 128
The potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Rothman, D. L., de Graaf, R. A., Hyder, F., Mason, G. F., Behar, K. L., & De Feyter, H. M. (2019) · NMR in Biomedicine · doi:10.1002/nbm.4172 · Cited by 53
Metadata
- Authors
- Kuzniecky, R., Ho, S., Pan, J., Martin, R., Gilliam, F., Faught, E., & Hetherington, H.
- Venue
- Neurology
- Published
- 2002-02-12
- Volume
- 58
- Issue
- 3
- Pages
- 368-372
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2040073841
- Cited by
- 174
- References
- 0
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.